Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
16
04
2019
revised:
05
07
2019
accepted:
29
07
2019
pubmed:
23
8
2019
medline:
19
5
2020
entrez:
23
8
2019
Statut:
ppublish
Résumé
Gray matter (GM) pathology is closely associated with physical and cognitive impairment in persons with multiple sclerosis (PwMS). Similarly, serum neurofilament light chain (sNfL) levels are related to MS disease activity and progression. To assess the cross-sectional and longitudinal associations between sNfL and MRI-derived lesion and brain volume outcomes in PwMS and age-matched healthy controls (HCs). Forty-seven HCs and 120 PwMS were followed over 5 years. All subjects underwent baseline and follow-up 3T MRI and sNfL examinations. Lesion volumes (LV) and global, tissue-specific and regional brain volumes were assessed. sNfL levels were analyzed using single molecule array (Simoa) assay and quantified in pg/mL. The associations between sNfL levels and MRI outcomes were investigated using regression analyses adjusted for age, sex, baseline disease modifying treatment (DMT) use and change in DMT over the follow-up. False discovery rate (FDR)-adjusted q-values <0.05 were considered significant. In PwMS, baseline sNfL was associated with baseline T Higher sNfL levels were associated with baseline LVs and greater development of GM atrophy in PwMS.
Sections du résumé
BACKGROUND
Gray matter (GM) pathology is closely associated with physical and cognitive impairment in persons with multiple sclerosis (PwMS). Similarly, serum neurofilament light chain (sNfL) levels are related to MS disease activity and progression.
OBJECTIVES
To assess the cross-sectional and longitudinal associations between sNfL and MRI-derived lesion and brain volume outcomes in PwMS and age-matched healthy controls (HCs).
MATERIALS AND METHODS
Forty-seven HCs and 120 PwMS were followed over 5 years. All subjects underwent baseline and follow-up 3T MRI and sNfL examinations. Lesion volumes (LV) and global, tissue-specific and regional brain volumes were assessed. sNfL levels were analyzed using single molecule array (Simoa) assay and quantified in pg/mL. The associations between sNfL levels and MRI outcomes were investigated using regression analyses adjusted for age, sex, baseline disease modifying treatment (DMT) use and change in DMT over the follow-up. False discovery rate (FDR)-adjusted q-values <0.05 were considered significant.
RESULTS
In PwMS, baseline sNfL was associated with baseline T
CONCLUSION
Higher sNfL levels were associated with baseline LVs and greater development of GM atrophy in PwMS.
Identifiants
pubmed: 31437387
doi: 10.1002/acn3.50872
pmc: PMC6764487
doi:
Substances chimiques
Neurofilament Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1757-1770Subventions
Organisme : Novartis Pharma AG, Basel, Switzerland
Pays : International
Organisme : Swiss National Research Foundation
ID : 320030_160221
Pays : International
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
© 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Références
Neuroimage. 2012 Jan 2;59(1):331-9
pubmed: 21820063
Nat Rev Neurol. 2014 Aug;10(8):459-68
pubmed: 25002107
Lancet Neurol. 2014 Jan;13(1):113-26
pubmed: 24331797
Clin Chem Lab Med. 2016 Oct 1;54(10):1655-61
pubmed: 27071153
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Brain. 2018 Aug 1;141(8):2382-2391
pubmed: 29860296
Lancet Neurol. 2015 Feb;14(2):183-93
pubmed: 25772897
Nat Rev Neurol. 2011 May 10;7(6):332-42
pubmed: 21556031
Neuroimage. 2011 Jun 1;56(3):907-22
pubmed: 21352927
Brain. 2016 Mar;139(Pt 3):807-15
pubmed: 26912645
Hum Brain Mapp. 2012 Dec;33(12):2802-14
pubmed: 21976406
Neurology. 2015 Jul 7;85(1):18-28
pubmed: 25888557
Lancet Neurol. 2012 Dec;11(12):1082-92
pubmed: 23153407
J Neuroimaging. 2017 Jan;27(1):107-113
pubmed: 27239049
Ann Neurol. 2018 Feb;83(2):223-234
pubmed: 29328531
Brain. 2013 Jun;136(Pt 6):1799-815
pubmed: 23687122
Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491
pubmed: 30564615
Neurology. 2019 Feb 12;92(7):e733-e741
pubmed: 30635483
Radiology. 2018 Nov;289(2):487-496
pubmed: 30015589
Ann Neurol. 2010 Oct;68(4):477-93
pubmed: 20976767
N Engl J Med. 1998 Jan 29;338(5):278-85
pubmed: 9445407
Neuroimage. 2018 Feb 15;167:438-452
pubmed: 29097315
J Neurol Sci. 2018 Oct 15;393:128-134
pubmed: 30165291
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Brain. 2017 Mar 1;140(3):527-546
pubmed: 27794524
Brain. 2018 Jun 1;141(6):1665-1677
pubmed: 29741648
Radiology. 2013 Sep;268(3):831-41
pubmed: 23613615
Neurology. 2019 Mar 5;92(10):e1007-e1015
pubmed: 30737333
Expert Rev Neurother. 2016 Jul;16(7):777-93
pubmed: 27105209
AJNR Am J Neuroradiol. 2018 Aug;39(8):1480-1486
pubmed: 29976833
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
Ann Neurol. 2008 Sep;64(3):255-65
pubmed: 18661561
Brain. 2016 Jan;139(Pt 1):115-26
pubmed: 26637488
J Neuroimaging. 2018 Sep;28(5):490-495
pubmed: 29856910
Brain. 2012 Oct;135(Pt 10):2938-51
pubmed: 23065787
Neuroimage. 2014 Apr 15;90:207-17
pubmed: 24333394
Eur J Neurol. 2019 Jan;26(1):87-e8
pubmed: 30103277
Ann Neurol. 2018 Feb;83(2):210-222
pubmed: 29331092
Nat Rev Neurol. 2019 Jun;15(6):329-342
pubmed: 31000816
Nat Rev Neurol. 2014 Apr;10(4):225-38
pubmed: 24638138
Mult Scler. 2017 Sep;23(10):1336-1345
pubmed: 27811339
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
Lancet Neurol. 2002 Aug;1(4):232-41
pubmed: 12849456